3-碘-4-三氟甲基苯甲酸 | 1034690-61-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-碘-4-三氟甲基苯甲酸
• 英文名称: 3-iodo-4-(trifluoromethyl)benzoic acid
• CAS: 1034690-61-3
• 化学式: C₈H₄F₃IO₂
• 分子量: 316.018
• InChiKey: WNJDSOAQPKABJD-UHFFFAOYSA-N

物化性质

• 沸点：
  324.0±42.0 °C(Predicted)
• 密度：
  2.005±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-碘-4-三氟甲基苯甲酸 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 生成
  参考文献：
  名称：

  Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors

  摘要：

  FGF receptors (FGFRs) are tyrosine kinases that are overexpressed in diverse tumors by genetic alterations such as gene amplifications, somatic mutations and translocations. Owing to this characteristic, FGFRs are attractive targets for cancer treatment. It has been demonstrated that most multi-targeted, ATP competitive tyrosine kinase inhibitors are active against FGFRs as well as other kinases. The design of new and more selective inhibitors of FGFRs, which might be reduced off-target and side effects, is a difficult yet significant challenge. The results of the current investigation, show that novel Ponatinib analogues are highly active as FGFR inhibitors and that they possess reduced kinase insert domain receptor (KDR) activities. Observations made in a structure and activity relationship (SAR) investigation led to the development of a promising, orally available lead compound 4, which displays a 50-100 fold in vitro selectivity for inhibition of FGFR1-3 over KDR. In addition, biological evaluation of compound 4 showed that it displays significant antitumor activities in FGFR1-amplificated H1581 and FGFR2amplificated SNU-16 xenograft models. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.10.003
• 作为产物：
  描述：

  3-硝基-4-三氟甲基苯甲酸 在 palladium on activated charcoal 硫酸 、 氢气 、 sodium nitrite 作用下， 以 水 、 乙酸乙酯 为溶剂， -5.0~20.0 ℃ 、275.8 kPa 条件下， 反应 6.0h， 生成 3-碘-4-三氟甲基苯甲酸
  参考文献：
  名称：

  CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S

  摘要：

  描述了与碳相连的四氢吡唑吡啶化合物，这些化合物可作为cathepsin S调节剂。这些化合物可用于制备药物组合物和治疗疾病状态、疾病和病况的方法，这些疾病状态、疾病和病况是由cathepsin S活性介导的，如银屑病、疼痛、多发性硬化症、动脉粥样硬化和类风湿性关节炎。

  公开号：

  US20080200454A1

文献信息

• Formamide as an Unconventional Amine Protecting Group for PET Radiochemistry
  作者：Jimmy Erik Jakobsson、Gaute Grønnevik、Waqas Rafique、Karoline Hartvig、Patrick Johannes Riss

  DOI：10.1002/ejoc.201800554

  日期：2018.8.1

  yielding radiochemistry adapted protocol utilising formamides as masking groups for secondary and tertiary amines. Selective reducing conditions were devised using borane reagents. In this protocol formamide functionalities were found to have an orthogonal reactivity to most other carbonyl functions, while effectively protecting amines from oxidative degradation. We exemplify the newly developed methodology

  我们使用甲酰胺作为仲胺和叔胺的掩蔽基团，开发了一种通用，快速且可靠的高产放射化学适应方案。使用硼烷试剂设计了选择性还原条件。在该方案中，发现甲酰胺官能团与大多数其他羰基官能团具有正交反应性，同时有效保护胺免于氧化降解。我们通过合成μ阿片类PET放射性示踪剂和多巴胺PET放射性示踪剂类似物来举例说明新开发的方法。
• INDOLE DERIVATIVES AS S1P1 RECEPTOR
  申请人：AHMED Mahmood

  公开号：US20100113796A1

  公开（公告）日：2010-05-06

  The invention relates to compounds of formula (I) wherein one of R 5 and R 6 is hydrogen or R 2 and the other is (a) pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.

  本发明涉及化合物的公式(I)，其中R5和R6中的一个是氢或R2，另一个是(a)。还涉及含有这些化合物的药物组合物，以及它们在治疗通过S1P1受体介导的疾病或疾病方面的用途。
• Indole derivatives as S1P1 Receptor
  申请人：Glaxo Group Limited

  公开号：US08101775B2

  公开（公告）日：2012-01-24

  The invention relates to compounds of formula (I) wherein one of R5 and R6 is hydrogen or R2 and the other is (a) pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.

  本发明涉及式(I)的化合物，其中R5和R6中的一个是氢或R2，另一个是（a）含有它们的药物组合物以及它们在治疗通过S1P1受体介导的疾病或疾病状态中的应用。
• Indole derivatives as S1P1 receptor agonists
  申请人：Glaxo Group Limited

  公开号：EP2206710A1

  公开（公告）日：2010-07-14

  The invention relates to compounds of formula (I) wherein one of R5 and R6 is hydrogen or R2 and the other is (a) processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.

  本发明涉及式 (I) 的化合物 其中 R5 和 R6 中的一个是氢或 R2，另一个是 (a) 它们的制备工艺、含有它们的药物组合物以及它们在治疗通过 S1P1 受体介导的病症或紊乱中的用途。
• WO2008/74821
  申请人：——

  公开号：——

  公开（公告）日：——